糖尿病混合型高脂血症临床治疗分析

目的观察血脂康与罗格列酮联合用药对2型糖尿病合并混合型高脂血症的影响。方法56例门诊厦住院的2型糖尿病合并混合型高脂血症的病人随机分成治疗组28例，应用血脂康胶囊0．6g／2）L／d，罗格列酮片4ms／1次／d；对照组28例，单独使用血脂康胶囊0．6昏／2挺／d。治疗16周，抽血查治疗前与治疗后血清胆固醇（代）、高密度脂蛋白（HDL—C）、低密度脂蛋白（LDL—C）、甘油三脂（TG）厦前脂蛋白-a（IjP—a）水平。结果两组治疗后TC、HDL—C、LDL—C、LP—a水平较治疗前均有显著下降（P〈0．01），两组间TG下降幅度差异有显著性（P〈0．05），治疗组较对照组TG下降幅度明显增大。蛄论血脂康与罗格列酮联合治疗2型糖尿病合并混合型高脂血症效果较好，尤其是合并有高甘油三脂血症者。

Observation on the effect of Xuezhikang and Rosiglitazone on diabetes patients complicated with hyperlipidemia

Objective To evaluate the effect of Xuezhika in combination with rosiglitazone on type 2 diabetic patients with mixed hyperlipidemia. Methods Fifty-six diabetic patients with mixed hyperlipidemia were randomly divided into two groups, each with 28 patients. Patients in Group I were given capsules Xuezhika 0.6g twice daily and tablets rosiglitazone 4mg once daily; patients in Group II received capsules Xuezhika 0.6g twice daily for a course of 16 weeks. Fasting lipid profile was analyzed at week 0 and week 16. Results The levels of serum total cholesterol(TC), LDL cholesterol(LDL-C), and lipoprotein(a) Lp(a)] decreased remarkably in the two groups 16 weeks after treatment (P<0.01). The level of triglyceride(TG) decreased slightly in group II, but decreased significantly in group I, there was significant difference between the two groups (P<0.05). Conclusion Xuezhika in combination with rosiglitazone is effect on type 2 diabetic patients with mixed hyperlipidemia, especially on those with hypertriglyceridemia.